The Patent Finder

Humanised anti-interleukin-18 antibody

Glaxo Group Limited

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 3 of these applications claim priority to application 11/752,707, filed May 23, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 10,703,814A Method of Treatment with Humanized ANTI-IL-18 Antibodies
In force
 · High confidence
UsedRemaining
Glaxo Group LimitedIn forceHigh confidence
US 8,637,018Humanized ANTI-IL-18 Antibodies
In force
 · High confidence
Glaxo Group LimitedIn forceHigh confidence
US 9,499,617Humanized ANTI-IL-18 Antibodies
In force
 · High confidence
Glaxo Group LimitedIn forceHigh confidence
US 8,133,978Humanised anti-interleukin-18 antibody
In force
 · High confidence
Glaxo Group LimitedIn forceHigh confidence
Application 15/293,823Immunoglobulins
Abandoned
Abandoned Mar 5, 2019
Glaxo Group LimitedAbandonedAbandoned Mar 5, 2019
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Glaxo Group Limited.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited